Logo image of RVPH

REVIVA PHARMACEUTICALS HOLDI (RVPH) Stock Fundamental Analysis

NASDAQ:RVPH - Nasdaq - US76152G1004 - Common Stock - Currency: USD

0.89  +0.01 (+1.48%)

After market: 0.9 +0.01 (+1.12%)

Fundamental Rating

1

Overall RVPH gets a fundamental rating of 1 out of 10. We evaluated RVPH against 198 industry peers in the Pharmaceuticals industry. RVPH may be in some trouble as it scores bad on both profitability and health. RVPH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RVPH has reported negative net income.
In the past year RVPH has reported a negative cash flow from operations.
RVPH had negative earnings in 4 of the past 5 years.
RVPH had a negative operating cash flow in each of the past 5 years.
RVPH Yearly Net Income VS EBIT VS OCF VS FCFRVPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

RVPH's Return On Assets of -192.99% is on the low side compared to the rest of the industry. RVPH is outperformed by 87.37% of its industry peers.
With a Return On Equity value of -3680.05%, RVPH is not doing good in the industry: 84.34% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -192.99%
ROE -3680.05%
ROIC N/A
ROA(3y)-169.33%
ROA(5y)-106.82%
ROE(3y)-1567.74%
ROE(5y)-946.37%
ROIC(3y)N/A
ROIC(5y)N/A
RVPH Yearly ROA, ROE, ROICRVPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RVPH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RVPH Yearly Profit, Operating, Gross MarginsRVPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

1

2. Health

2.1 Basic Checks

RVPH has more shares outstanding than it did 1 year ago.
The number of shares outstanding for RVPH has been increased compared to 5 years ago.
Compared to 1 year ago, RVPH has a worse debt to assets ratio.
RVPH Yearly Shares OutstandingRVPH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RVPH Yearly Total Debt VS Total AssetsRVPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -19.71, we must say that RVPH is in the distress zone and has some risk of bankruptcy.
RVPH has a worse Altman-Z score (-19.71) than 82.83% of its industry peers.
RVPH has a Debt/Equity ratio of 0.56. This is a neutral value indicating RVPH is somewhat dependend on debt financing.
RVPH's Debt to Equity ratio of 0.56 is on the low side compared to the rest of the industry. RVPH is outperformed by 62.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Altman-Z -19.71
ROIC/WACCN/A
WACCN/A
RVPH Yearly LT Debt VS Equity VS FCFRVPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 1.01 indicates that RVPH should not have too much problems paying its short term obligations.
The Current ratio of RVPH (1.01) is worse than 82.32% of its industry peers.
A Quick Ratio of 1.01 indicates that RVPH should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.01, RVPH is doing worse than 75.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 1.01
RVPH Yearly Current Assets VS Current LiabilitesRVPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

RVPH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.51%, which is quite impressive.
EPS 1Y (TTM)44.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RVPH will show a very strong growth in Earnings Per Share. The EPS will grow by 24.55% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.8%
EPS Next 2Y12.06%
EPS Next 3Y18.23%
EPS Next 5Y24.55%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RVPH Yearly Revenue VS EstimatesRVPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
RVPH Yearly EPS VS EstimatesRVPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RVPH. In the last year negative earnings were reported.
Also next year RVPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RVPH Price Earnings VS Forward Price EarningsRVPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RVPH Per share dataRVPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as RVPH's earnings are expected to grow with 18.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.06%
EPS Next 3Y18.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RVPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REVIVA PHARMACEUTICALS HOLDI

NASDAQ:RVPH (4/30/2025, 8:00:01 PM)

After market: 0.9 +0.01 (+1.12%)

0.89

+0.01 (+1.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-31 2025-03-31/amc
Earnings (Next)05-19 2025-05-19
Inst Owners29.39%
Inst Owner Change0.1%
Ins Owners10.17%
Ins Owner Change0%
Market Cap41.60M
Analysts81.67
Price Target10.93 (1128.09%)
Short Float %9.13%
Short Ratio4.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.98%
Min EPS beat(2)0.37%
Max EPS beat(2)31.6%
EPS beat(4)4
Avg EPS beat(4)19.75%
Min EPS beat(4)0.37%
Max EPS beat(4)34.93%
EPS beat(8)6
Avg EPS beat(8)-2.76%
EPS beat(12)8
Avg EPS beat(12)-6.19%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.76%
PT rev (3m)-29.51%
EPS NQ rev (1m)21.51%
EPS NQ rev (3m)26.01%
EPS NY rev (1m)17.25%
EPS NY rev (3m)22.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 51.23
P/tB 51.23
EV/EBITDA N/A
EPS(TTM)-0.91
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -192.99%
ROE -3680.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-169.33%
ROA(5y)-106.82%
ROE(3y)-1567.74%
ROE(5y)-946.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.01
Quick Ratio 1.01
Altman-Z -19.71
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.14%
EPS Next Y25.8%
EPS Next 2Y12.06%
EPS Next 3Y18.23%
EPS Next 5Y24.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-18.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.43%
OCF growth 3YN/A
OCF growth 5YN/A